The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
ApexOnco Front Page
Recent articles
Daraxonrasib scores a plenary session late-breaker.
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
A look at big oncology deals since 2016 finds outright success stories hard to come by.
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.